<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35438459</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1179-1942</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drug safety</Title>
          <ISOAbbreviation>Drug Saf</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-022-01175-2</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Regulatory advisories on hydroxyzine and risk of QT prolongation and Torsade de pointes (TdP) were issued in the UK in April 2015 and Canada in June 2016. We hypothesized patients with risk factors for QT prolongation and TdP, compared with those without risk factors, would be less likely to initiate hydroxyzine in the UK and in British Columbia (BC), Canada, following advisories.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a longitudinal study with repeated measures, and evaluated hydroxyzine initiation in a UK cohort and a concurrent BC control cohort (April 2013-March 2016) as well as in a BC advisory cohort (June 2014-May 2017).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">This study included 247,665 patients in the UK cohort, 297,147 patients in the BC control cohort, and 303,653 patients in the BC advisory cohort. Over a 12-month post-advisory period, hydroxyzine initiation decreased by 21% in the UK (rate ratio 0.79, 95% confidence interval 0.66-0.96) relative to the expected level of initiation based on the pre-advisory trend. Hydroxyzine initiation did not change in the BC control cohort or following the Canadian advisory in the BC advisory cohort. The decrease in hydroxyzine initiation in the UK in the 12 months after the advisories was not significantly different for patients with risk factors compared with those without risk factors.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hydroxyzine initiation decreased in the UK, but not in BC, in the 12 months following safety advisories. The decrease in hydroxyzine initiation in the UK was not significantly different for patients with versus without risk factors for QT prolongation and TdP.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Morrow</LastName>
            <ForeName>Richard L</ForeName>
            <Initials>RL</Initials>
            <Identifier Source="ORCID">0000-0002-5869-5197</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 210-1110 Government St., Victoria, BC, V8W 1Y2, Canada. richard.morrow@ubc.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mintzes</LastName>
            <ForeName>Barbara</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine and Health and Charles Perkins Centre, School of Pharmacy, University of Sydney, Sydney, NSW, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Souverein</LastName>
            <ForeName>Patrick C</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hallgreen</LastName>
            <ForeName>Christine E</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Faculty of Health and Medical Sciences, Copenhagen Centre for Regulatory Science, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmed</LastName>
            <ForeName>Bilal</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 210-1110 Government St., Victoria, BC, V8W 1Y2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roughead</LastName>
            <ForeName>Elizabeth E</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Bruin</LastName>
            <ForeName>Marie L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Faculty of Health and Medical Sciences, Copenhagen Centre for Regulatory Science, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kristiansen</LastName>
            <ForeName>Sarah Brøgger</ForeName>
            <Initials>SB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Drug Design and Pharmacology, Pharmacovigilance Research Center, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lexchin</LastName>
            <ForeName>Joel</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Health, York University, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kemp-Casey</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sketris</LastName>
            <ForeName>Ingrid</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mangin</LastName>
            <ForeName>Dee</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pearson</LastName>
            <ForeName>Sallie-Anne</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puil</LastName>
            <ForeName>Lorri</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopert</LastName>
            <ForeName>Ruth</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Policy and Management, George Washington University, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bero</LastName>
            <ForeName>Lisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine and Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gnjidic</LastName>
            <ForeName>Danijela</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine and Health and Charles Perkins Centre, School of Pharmacy, University of Sydney, Sydney, NSW, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarpatwari</LastName>
            <ForeName>Ameet</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dormuth</LastName>
            <ForeName>Colin R</ForeName>
            <Initials>CR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 210-1110 Government St., Victoria, BC, V8W 1Y2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>PJT-153275</GrantID>
            <Acronym>CAPMC</Acronym>
            <Agency> CIHR</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drug Saf</MedlineTA>
        <NlmUniqueID>9002928</NlmUniqueID>
        <ISSNLinking>0114-5916</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>12</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35438459</ArticleId>
        <ArticleId IdType="doi">10.1007/s40264-022-01175-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s40264-022-01175-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Perry LT, Bhasale A, Fabbri A, Lexchin J, Puil L, Joarder M, et al. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States—2007 to 2016. Pharmacoepidemiol Drug Saf. 2020;29(9):1054–63. https://doi.org/10.1002/pds.5072 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.5072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012;50(6):466–78. https://doi.org/10.1097/MLR.0b013e318245a160 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MLR.0b013e318245a160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georgi U, Lammel J, Datzmann T, Schmitt J, Deckert S. Do drug-related safety warnings have the expected impact on drug therapy? A systematic review. Pharmacoepidemiol Drug Saf. 2020;29(3):229–51. https://doi.org/10.1002/pds.4968 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.4968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012;35(5):373–85. https://doi.org/10.2165/11599100-000000000-00000 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11599100-000000000-00000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weatherburn CJ, Guthrie B, Dreischulte T, Morales DR. Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis. Br J Clin Pharmacol. 2020;86(4):698–710. https://doi.org/10.1111/bcp.14104 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.14104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu JC, Cheng CL, Ross-Degnan D, Wagner AK, Zhang F, Kao Yang YH, et al. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. Pharmacoepidemiol Drug Saf. 2015;24(10):1026–35. https://doi.org/10.1002/pds.3834 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.3834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open medicine. 2010;4(1):e50–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel H, Calip GS, DiDomenico RJ, Schumock GT, Suda KJ, Lee TA. Prevalence of Cardiac Risk Factors in Patients Prescribed Azithromycin before and after the 2012 FDA Warning on the Risk of Potentially Fatal Heart Rhythms. Pharmacotherapy. 2020;40(2):107–15. https://doi.org/10.1002/phar.2355 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.2355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>UCB Pharma, Alliance Pharmaceuticals. New restrictions for hydroxyzine-containing medicines to further minimize the known risk of QT prolongation 2015. https://assets.publishing.service.gov.uk/media/553faae3ed915d15d800002c/Hydroxyzine_DHPC_sent_27_April_2015.pdf . Accessed 5 Feb 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency. Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes. 29 April 2015. https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes . Accessed 13 Nov 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Erfa Canada. ATARAX (hydroxyzine) – Risk of QT Prolongation and Torsade de Pointes. 2016. https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58758a-eng.php . Accessed 5 Feb 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Canadian Pharmacists Association. HYDROXYZINE (CPhA monograph) Ottawa, ON. 2021. www.myrxtx.ca . Accessed 5 Aug 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines [updated 27 Mar 2015]. https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine_en.pdf . Accessed 11 Sep 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28(6):964–78 (discussion 2-3).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2006.06.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzmaurice G, Laird N, Ware J. Applied longitudinal analysis. Hoboken, NJ: John Wiley &amp; Sons; 2004.</Citation>
        </Reference>
        <Reference>
          <Citation>Gallagher AM, Dedman D, Padmanabhan S, Leufkens HGM, de Vries F. The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations. Pharmacoepidemiol Drug Saf. 2019;28(5):563–9. https://doi.org/10.1002/pds.4747 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.4747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kontopantelis E, Stevens RJ, Helms PJ, Edwards D, Doran T, Ashcroft DM. Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study. BMJ Open. 2018;8(2): e020738. https://doi.org/10.1136/bmjopen-2017-020738 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2017-020738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>British Columbia Ministry of Health. Consolidation File (MSP Registration &amp; Premium Billing). Vancouver: Population Data BC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>British Columbia Ministry of Health. Medical services plan (MSP) payment information file. Vancouver: Population Data BC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>British Columbia Ministry of Health. PharmaNet. Vancouver: Population Data BC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>British Columbia Ministry of Health. Vital events deaths. Vancouver: Population Data BC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Canadian Institute for Health Information. Discharge abstract database (Hospital Separations). Vancouver: Population Data BC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Government of Canada. Federal Public Drug Benefit Programs Ottawa, ON. Updated 11 Apr 2019. https://www.canada.ca/en/health-canada/services/health-care-system/pharmaceuticals/access-insurance-coverage-prescription-medicines/federal-public-drug-benefit-programs.html . Accessed 6 Aug 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Franklin JM, Mahesri M, Krumme AA, Barberio J, Fischer MA, Brill G, et al. Time to filling of new prescriptions for chronic disease medications among a cohort of elderly patients in the USA. J Gen Intern Med. 2018;33(11):1877–84. https://doi.org/10.1007/s11606-018-4592-6 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11606-018-4592-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13. https://doi.org/10.1016/j.psym.2012.11.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psym.2012.11.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blancett JR, Smith KM, Akers WS, Flynn JD. Staying in rhythm: identifying risk factors for Torsade de pointes. Orthopedics. 2005;28(12):1417–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3928/0147-7447-20051201-11</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal. 2012;2012: 212178. https://doi.org/10.1100/2012/212178 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1100/2012/212178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin. 2009;98(4):208–12. https://doi.org/10.1007/s00392-008-0741-y .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00392-008-0741-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139–52. https://doi.org/10.1177/1715163516641136 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1715163516641136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–26. https://doi.org/10.1185/03007995.2013.840568 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007995.2013.840568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16–25. https://doi.org/10.1007/s11096-016-0414-2 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11096-016-0414-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachos K, Georgopoulos S, Efremidis M, Sideris A, Letsas KP. An update on risk factors for drug-induced arrhythmias. Expert Rev Clin Pharmacol. 2016;9(1):117–27. https://doi.org/10.1586/17512433.2016.1100073 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/17512433.2016.1100073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: what does it offer? Trends Cardiovasc Med. 2018;28(2):94–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcm.2017.07.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Interactions: Inducers, Inhibitors, and Substrates. Geri-RxFiles: Assessing Medications in Older Adults. 2019. www.rxfiles.ca/RxFiles/uploads/documents/members/Cht-Drug-Interactions-Geri.pdf . Accessed 30 Jun 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Dave DJ. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011;2(4):230–5. https://doi.org/10.4103/0976-500X.85934 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0976-500X.85934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab. 2014;15(7):651–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1389200215666141125121511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-2 . Accessed 29 Jun 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138920008784220664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Electrolyte imbalances in older adults. Geri-RxFiles. 2019. https://www.rxfiles.ca/RxFiles/uploads/documents/members/Geri-RxFiles-Electrolytes.pdf . Accessed 29 Jun 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Ethier J. Potassium disturbances Ottawa: Canadian Pharmacists Association; 2018. www.myrxtx.ca . Accessed 25 May 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Veltri KT, Mason C. Medication-induced hypokalemia. P T. 2015;40(3):185–90.</Citation>
        </Reference>
        <Reference>
          <Citation>Bardal SK, Waechter JE, Martin DS. Applied pharmacology. St. Louis: Elsevier Saunders; 2011.</Citation>
        </Reference>
        <Reference>
          <Citation>Ovsyshcher IE, Barold SS. Drug induced bradycardia: to pace or not to pace? Pacing Clin Electrophysiol. 2004;27(8):1144–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1540-8159.2004.00597.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wung SF. Bradyarrhythmias: clinical presentation, diagnosis, and management. Crit Care Nurs Clin N Am. 2016;28(3):297–308. https://doi.org/10.1016/j.cnc.2016.04.003 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cnc.2016.04.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dormuth CR, Maclure M, Glynn RJ, Neumann P, Brookhart AM, Schneeweiss S. Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther. 2008. https://doi.org/10.1016/j.clinthera.2008.06.003 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2008.06.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2307/2531248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales DR, Macfarlane T, MacDonald TM, Hallas J, Ernst MT, Herings RMC, et al. Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. Pharmacoepidemiol Drug Saf. 2021;30(4):482–91. https://doi.org/10.1002/pds.5191 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.5191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhasale AL, Sarpatwari A, Lipworth W, Mollebaek M, McEwin EJ, Gautam N, et al. Regulatory authority and clinical acceptability: Physicians’ responses to regulatory drug safety warnings. Br J Clin Pharmacol. 2022;88(2):713–22. https://doi.org/10.1111/bcp.15007 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.15007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. PRAC recommends new measures to minimise known heart risks of hydroxyzine-containing medicines [updated 13 Feb 2015]. https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-prac-recommends-new-measures-minimise-known-heart-risks-hydroxyzine_en.pdf . Accessed 24 Jan 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Mollebaek M, Kaae S. Why do general practitioners disregard direct to healthcare professional communication? A user-oriented evaluation to improve drug safety communication. Basic Clin Pharmacol Toxicol. 2020;11:11. https://doi.org/10.1111/bcpt.13516 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcpt.13516</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
